Search clinical trials for: [14C] Selpercatinib

Total 2784 results

Eli Lilly and Company
Loxo Oncology, Inc.

Completed

A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants

Healthy

United States
Hoffmann-La Roche

Completed

Mass Balance and Absolute Bioavailability Study of RO7049389 in Healthy Volunteers

Healthy Volunteers

United Kingdom
Vivozon, Inc.

Completed

Absorption, Metabolism, Excretion, and Mass Balance Study of [14C]-VVZ-149 in Healthy Adult Male Subjects

Healthy Adult Male

United States
Rachel Lieberman

Terminated

Capsular Tension Rings in Intraocular Lens Rotation

Cataract | Ophthalmoplegia | Ophthalmologic Complication

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation (LIBRETTO-321)

Solid Tumor | Medullary Thyroid Cancer

China
Eli Lilly and Company
Loxo Oncology, Inc.

Completed

A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants

Healthy | Hepatic Impairment

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Completed

A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants

Healthy

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Completed

A Study of Selpercatinib (LY3527723) in Healthy Participants

Healthy

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Available

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Breast Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Colon Cancer | Medullary Thyroid Cancer | Papillary Thyroid Cancer | Other Solid Tumors With Evidence of Activating RET Alteration

Spain, United States, Australia, France, Germany, Israel, Italy, Japan, New Zealand, Poland, Singapore, Switzerland
Loxo Oncology, Inc.
Eli Lilly and Company

Completed

A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants

Healthy

Singapore
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432)

Carcinoma, Non-Small-Cell Lung

United States, Denmark, Taiwan, China, Canada, Spain, Japan, Germany, United Kingdom, Brazil, India, Korea, Republic of, Australia, Italy, Norway, Israel, Greece, Turkey, Netherlands, Austria, Belgium, Hong Kong, Poland, Puerto Rico, Russian... and more
Eli Lilly and Company
Loxo Oncology, Inc.

Completed

A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function

Healthy | Renal Insufficiency

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Completed

A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants

Healthy

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)

Medullary Thyroid Cancer

United States, Canada, Spain, China, Taiwan, Australia, Japan, India, Belgium, Germany, France, Netherlands, Czechia, Brazil, Korea, Republic of, United Kingdom, Italy, Israel, Greece, Poland, Russian Federation
Taisho Pharmaceutical Co., Ltd.

Completed

Mass Balance Study of TS-142 in Healthy Adult Subjects.

Healthy Male Subjects

Japan
Hoffmann-La Roche

Completed

A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)

Solid Tumors

Hungary
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors (LIBRETTO-121)

Soft Tissue Sarcoma | Medullary Thyroid Cancer | Papillary Thyroid Cancer | Infantile Fibrosarcoma | Infantile Myofibromatosis

United States, Australia, Japan, Canada, Germany, Korea, Republic of, France, Spain, United Kingdom, Denmark, Italy
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (LIBRETTO-001)

Non-Small Cell Lung Cancer | Colon Cancer | Medullary Thyroid Cancer | Any Solid Tumor

United States, Japan, Taiwan, Australia, Korea, Republic of, Israel, Spain, Switzerland, Singapore, France, Canada, Italy, Germany, United Kingdom, Hong Kong, Denmark
Laekna Limited

Completed

Human Mass Balance and Biotransformation Study of [14C]Afuresertib

Healthy Volunteer

China
Arcus Biosciences, Inc.
Gilead Sciences

Completed

A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer

Healthy Participants

Netherlands
Indivior Inc.

Completed

Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants

Opioid Use Disorder

United States
Biogen
Denali Therapeutics Inc.

Completed

A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects

Healthy Volunteers

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Completed

A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants

Healthy

United States
Massachusetts General Hospital
Eli Lilly and Company

Recruiting

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

Thyroid Carcinoma | Thyroid Cancer | Papillary Thyroid Cancer | Metastatic Thyroid Cancer | Follicular Thyroid Cancer | Unresectable Thyroid Gland Carcinoma

United States
Reata, a wholly owned subsidiary of Biogen

Completed

A Human AME Study for Omaveloxolone

Healthy Male Subjects

United States
Cyclerion Therapeutics

Completed

A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Olinciguat in Healthy Male Volunteers

Healthy Volunteers

United States
Denovo Biopharma LLC

Completed

A Study of LY2140023 in Healthy Participants

Healthy Participants

United Kingdom
Athira Pharma
Alturas Analytics, Inc.; Labcorp Drug Development Inc

Completed

A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017)

Healthy Volunteers

United States
Biogen
Denali Therapeutics Inc.

Completed

A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects

Healthy Volunteers

United States
AstraZeneca
Quotient Sciences

Completed

Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD5718 in Volunteers

Cardiovascular Disease

United Kingdom
Celgene

Not yet recruiting

A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants

Healthy Volunteers

United States
Pfizer
Arvinas Estrogen Receptor, Inc.

Completed

A Study to Understand How the Study Medicine Called ARV-471 is Processed in Healthy Adults

Healthy

United States
H. Lundbeck A/S

Completed

Study Investigating the Safety and Tolerability of Lu AF88434 in Healthy Young Men

Healthy

Netherlands
Denali Therapeutics Inc.

Recruiting

A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants

Healthy Volunteers

United States
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Recruiting

The Mass Balance Study of [14C]JT001

Healthy Subjects

China
Impact Therapeutics, Inc.

Not yet recruiting

A Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 to China Healthy Male Subjects

Solid Tumor
Biogen

Completed

A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male Participants (Mass Balance)

Healthy Volunteer

United States
Rivus Pharmaceuticals, Inc.

Completed

A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6

Healthy

United States
Guangdong Raynovent Biotech Co., Ltd

Completed

Mass Balance Study of [14C]RAY1216 in Healthy Adult Male Subjects in China

Pharmacokinetics

China
Xizang Haisco Pharmaceutical Co., Ltd

Active, not recruiting

Pharmacokinetics, Mass Balance, and Metabolism of [14C]HSK31679 in Healthy Adult Male Volunteers.

Healthy

China
Shanghai Henlius Biotech

Completed

Mass Balance Study of [14C]HLX208 in China Healthy Subjects

Mass Balance Study in Healthy Subjects

China
Eli Lilly and Company

Completed

A Study of Carbon-14-Labelled [14C] LY3871801 in Healthy Male Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of Carbon-14-Labelled [14C] LY3556050 in Healthy Male Participants

Healthy

United States
Sunshine Lake Pharma Co., Ltd.

Completed

ADME Study of [14C]- Rongliflozin in Healthy Male Subjects

Healthy Adult Male Volunteers

China
Sunshine Lake Pharma Co., Ltd.

Completed

ADME Study of [14C]- Larotinib in Healthy Male Subjects

Healthy Adult Male Volunteers

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Mass Balance and Biotransformation Study of [14C]SKLB1028 in Chinese Healthy Male Subjects

Healthy Male Subjects

China
Corcept Therapeutics

Completed

Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Participants

Healthy

United Kingdom
BeiGene

Completed

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib in Participants With Advanced Cancer

Advanced Solid Tumors

United Kingdom
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study to Evaluate the Mass Babance and Biotransformation of [14C]SHR6390 in Healthy Adult Male Volunteers

Healthy Adult Male Volunteers

China

Search clinical trials for: [14C] Selpercatinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations